News|Articles|April 3, 2024

Pharma Pulse 4/3/24: Making AI Images Look Less Like AI, Ozempic Babies & more

The latest news for pharma industry insiders.

Barriers Impacting Patient Enrollment in Lung Cancer Trials

Systematic review of available literature aimed to identify the most prominent barriers affecting enrollment in oncology drug trials.

AstraZeneca Caps Inhaled Respiratory Portfolio at $35 For Eligible Patients With Asthma, COPD

The Asthma and Allergy Foundation of America applauded the efforts by AstraZeneca, saying accessibility and affordability can help reduce racial disparities in asthma.

How the Ad Industry Is Making AI Images Look Less Like AI

Users of generative artificial intelligence imagery are learning new tricks to avoid its shiny, sometimes seven-fingered look

DIA 2024 Global Annual Meeting Welcomes Life Sciences Leaders to Confront Emerging Challenges in Healthcare

The ethical use of artificial intelligence (AI) in healthcare, the development of advanced therapies, and other emerging regulatory and scientific challenges demand in-depth discussion for the DIA 2024 Global Annual Meeting, to be held June 16-20 in San Diego.

columbiamed on Threads:

Ozempic Babies: According to reproductive endocrinologist Dr. Alex Robles, "it’s possible that using medications like ozempic or Wegovy may improve a woman’s chances of conceiving if she has insulin resistance or obesity."

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.